Amplia Therapeutics Limited announced that the first patient has been dosed in the Company's Phase 1b/2a ACCENT clinical trial of focal adhesion kinase inhibitor AMP945. AMP945 targets focal adhesion kinase (FAK) and its use in the ACCENT trial is intended to enhance the efficacy of gemcitabine/nab-paclitaxel chemotherapy for people with advanced pancreatic cancer undergoing first-line treatment. Patients in the trial will receive AMP945 in addition to a standard treatment regimen with gemcitabine/nab-paclitaxel.

In a prior Phase 1 clinical trial of AMP945, conducted in healthy volunteers and completed in 2021, once daily oral doses of AMP945 showed excellent safety, tolerability and pharmacokinetic properties. AMP945 was also shown to inhibit FAK in skin samples provided by the healthy volunteers.